Good morning, and thank you for standing by. Welcome to Abbott's Third Quarter 2018 Earnings Conference Call. [Operator Instructions] This call is being recorded by Abbott. With the exception of any participant's questions asked during the question-and-answer session, the entire call, including the question-and-answer session, is material copyrighted by Abbott. It cannot be recorded or rebroadcast without Abbott's expressed written permission. I would now like to introduce Mr. Scott Leinenweber, Vice President, Investor Relations, Licensing and Acquisitions.

Good morning, and thank you for joining us. With me today are Miles White, Chairman of the Board and Chief Executive Officer; and Brian Yoor, Executive Vice President, Finance and Chief Financial Officer. Miles will provide opening remarks, and Brian will discuss our performance and outlook in more detail. Following their comments, Miles, Brian and I will take your questions. Before we get started, some statements made today may be forward-looking for purposes of the Private Securities Litigation Reform Act of 1995, including the expected financial results for 2018. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott's operations are discussed in Item 1A, Risk Factors, through our annual report on Securities and Exchange Commission Form 10-K for the year ended December 31, 2017. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law. Please note that third quarter financial results and guidance provided on the call today for sales, EPS and line items of the P&L will be for continuing operations only. On today's conference call, as in the past, non-GAAP financial measures will be used to help investors understand Abbott's ongoing business performance. These non-GAAP financial measures are reconciled with the comparable GAAP financial measures in our earnings news release and regulatory filings from today, which are available on our website at abbott.com. Unless otherwise noted, our commentary on sales growth refers to organic sales growth, which adjusts the 2017 basis of comparison to exclude the impact of exchange and historical results for Abbott's Medical Optics and St. Jude's vascular closure businesses, which were divested during the first quarter of 2017 as well as current and prior year sales for Alere, which was acquired on October 3, 2017. With that, I will now turn the call over to Miles.

Okay. Thanks, Scott, and good morning. Today, we reported results of another strong quarter with ongoing earnings per share of $0.75 along with sales growth of approximately 8% on an organic basis, reflecting well-balanced growth across all 4 of our businesses. I'm particularly pleased with the continued productivity of our new product pipeline and would like to highlight a couple areas where our products are creating and fundamentally shaping markets. I'll start with Structural Heart, where we're the world -- or the global leader in minimally invasive treatments for mitral regurgitation or a leaky heart valve. We've recently made several significant advancements in this area. In July, in the U.S., we initiated a pivotal trial for Tendyne, our device that's designed to replace damaged mitral heart valves without the need for open heart surgery. We also received U.S. FDA approval for our third-generation version of MitraClip, our market-leading device for the repair of mitral heart valve. And in September, we announced the results of our landmark COAPT trial, which demonstrated the MitraClip improved survival in clinical outcomes for patients with functional mitral regurgitation, the most prevalent form of this condition. We expect to submit this study data to the U.S. FDA in the coming weeks to support consideration of an expanded indication for MitraClip. These advancements will further enhance and strengthen our leadership position in this large and highly underpenetrated disease area and will bring new therapies to patients where effective treatment options are currently limited. Diabetes Care is another area where our technologies are making a big impact, specifically FreeStyle Libre, a revolutionary glucose monitoring system that eliminates the need for routine finger sticks. In the U.S., we received FDA approval for a 14-day sensor with a shorter 1-hour warm-up, making Libre the longest lasting wearable glucose sensor available.…

Thanks, Miles. As Scott mentioned earlier, please note that all references to sales growth rates, unless otherwise noted, are on an organic basis, which is consistent with our previous guidance. Turning to our results. Sales for the third quarter increased 7.8% on an organic basis. Rapid Diagnostics, which was acquired late last year and is therefore not included in our organic sales growth results, achieved sales of $481 million. Exchange had an unfavorable year-over-year impact of 2.7% on third quarter sales. During the quarter, we saw the U.S. dollar strengthened versus several currencies, resulting in a larger unfavorable impact on our results this quarter compared to the expectations had exchange rates held steady since the time of our earnings call in July. Regarding other aspects of the P&L, the adjusted gross margin ratio was 59.5% of sales, adjusted R&D investment was 7.3% of sales and adjusted SG&A expense is 29.7% of sales. Turning to our outlook for the full year 2018. We forecast organic sales growth of approximately 7%, at the top end of the guidance range we provided at the beginning of the year. At current rates, we expect exchange would now have a slightly negative impact on full year reported sales. In addition, we continue to expect Rapid Diagnostics to contribute sales of a little more than $2 billion. We forecast an adjusted gross margin ratio of around 59.5% of sales, which includes underlying gross margin improvement across our businesses. We forecast adjusted R&D investment of a little less than 7.5% of sales and adjusted SG&A expense of around 30.5% of sales. Turning to our outlook for the fourth quarter of 2018. We forecast an adjusted EPS of $0.80 to $0.82. We forecast organic sales growth of mid- to high single digits. And at current exchange rates, we'd expect exchange to have a negative impact of a little more than 3% on reported sales. In addition, we expect Rapid Diagnostics to contribute sales of around $500 million in the fourth quarter, which, as I previously mentioned, is not included in our organic growth rate this year. Before we open the call for questions, I'll now provide an overview of our fourth quarter organic sales growth outlook by business. For Established Pharmaceuticals, we forecast mid-single-digit sales growth, which reflects the difficult comparison in our noncore other business segment relative to the fourth quarter of last year when sales increased strong double digits. In Nutrition, we forecast low- to mid-single-digit sales growth. In Diagnostics, we forecast mid- to high-single-digit sales growth. And in Medical Devices, we forecast high-single-digit sales growth, which reflects double-digit growth in several areas of this business. With that, we will now open the call for questions.

[Operator Instructions] Our first question comes from David Lewis from Morgan Stanley.

We cannot hear the question, operator.

Can you hear me now?

Yes.

So Miles, 2 questions for you. Obviously, a lot of business momentum here in 2018 and meaningful drivers ahead, like Libre 2 and MitraClip. So as you think about sort of sustainability, is sort of 6% to 7% range sustainable over the intermediate term? And how are you feeling about Abbott's ability to deliver double digits or low teen earnings given the currency environment in all of these various opportunities to grow?

Okay. Thanks, David. Let me take the first part of that. The answer is sort of definitively and absolutely yes on the sustainability of earnings. In fact -- rather, sales top line, and I'll get to earnings in a minute. In that 6% to 7% range, I say yes. And frankly, I'm even looking at 7% and better. But if you look at the underlying momentum of each of these businesses today and the underlying growth of each of these businesses, there's actually some places, I think, it could get better. There's places we're, obviously, trying to improve. I wouldn't forecast it yet, but I still see plenty of growth, plenty of opportunity, frankly, with the new product pipeline for years to come. And you're seeing the evidence of that right now in the performance of all the businesses. The Diagnostics business growth rate is clearly turned up. That is clearly the impact of Alinity taking hold. It's having great success in Europe. Libre is doing super well. And on top of that, we haven't really put a lot of promotional emphasis behind it. So I see a strong future for both of those. The new product cadence coming out of Medical Devices is really good. And frankly, we expect another approval imminently here in the U.S. So I think that in terms of the sustainability of top line, I feel very good about that. I feel really good about the underlying growth of the company, the sustainability of it, et cetera. The little elephant in the room is clearly exchange. And I think that's true for practically every multinational out there. I think all of us, all investors, all companies doing business in international markets are experiencing the upturn in exchange now. And frankly, a bit of uncertainty about…

Okay. Miles, very clear. And the second, just a follow-up for you is just, can you help us put the Robert Ford announcement into perspective and sort of share your thoughts on what it means for you over the intermediate term?

Well, what it means to me over the intermediate term is I get a lot more help, which I'm happy about. Look, it's obviously a succession step. And one of the things that I think any good leader's got to do with his company is make sure that there's always good, strong succession, building, growing, et cetera, in the company. And that applies to me, too. So I think, for the continuity of the performance of this company, the continuity of its strategies, the continuity of it sustainable growth rates and so forth going forward, that's important. Robert Ford has been in this company this entire year. I've known him 22 years and pay a lot of attention to his career, as you might imagine. And he's been an excellent operator. He's handled our entire St. Jude integration, done a terrific job with Medical Devices. And consequently, I want all of those Medical Device businesses continuing to report directly to him, even as he takes on more responsibility. And I'd say, with time, this will develop pretty nicely. And I think it's a very good strong move for the company.

Our next question comes from Robbie Marcus from JPMorgan.

Miles, wanted to ask you about COAPT. A lot of us were at the TCT conference in San Diego last month and saw the great data there to a room of standing ovation, which we don't see in Medical Devices that often. So us on The Street, we can think about big numbers with such a large patient opportunity. Maybe tell us how you're thinking about MitraClip over the next few years and how you think The Street should be thinking about it.

Well, I'll tell you what. Obviously, the performance of MitraClip in that study was a real home run. And it's not often that studies are so definitively positive and so good in terms of their impact for patients. So we're, obviously, very happy about that and very proud of that. Our objective will be to move through the regulatory processes as rapidly as can be done and make it available for that use as rapidly as we can. I think the medical community sees tremendous medical benefit in that. And when you can make that kind of a difference, it's obviously big, important, good thing. And how rapidly we go through that regulatory process, hard to predict. We have not got a lot of -- well, we don't have any particular impact for next year in our roadmap for next year, at this point, for any impact from that product, so anything that happens is upside. And obviously, beyond that, I think it's got a pretty sizable opportunity. And it's not a broad mass market product, but the number of patients that will benefit from the product is significant. And so I think it will clearly make a difference in the overall performance of the company, this Medical Device business, the company, et cetera. It's not one that's going to get lost in rounding error, I can tell you that. Scott, do you want to add anything to that?

No, that's fair. We'll submit, as Miles mentioned in his prepared remarks, to the FDA in the coming weeks. And after that, it's in their hands, and we'll let that process play out.

Okay. Great. Maybe a follow-up on Libre. This is a product that's been wildly successful and now over $100 million run rate in the U.S., over $1 billion globally. And you really have one major competitor here that's, let's call it, at the upper end of the technology scale. And Abbott, I view as the low cost, easy to access, very easy-to-use product in continuous glucose monitoring. So as we think about the evolution of Libre over the next few years, how do you think about Libre staying at the lower end of the cost and ease-of-use curve versus moving up and trying to compete with your main competitor there?

Well, I'll tell you, interestingly enough, I don't actually look at it the way you just described. I think Libre is a pretty different product. It's a -- it's got tremendous capability. But given that value point that we have it priced at, it is accessible to patients all over the world. And when we first launched in Europe, we launched without any government reimbursement. And for the first time, glucose monitoring was patient pay. And it had wildly great acceptance just on that basis, which actually encouraged governments to reimburse the product. So I think with health care today, a lot of things that come to market are very expensive, whether they are pharmaceuticals or devices. And in this particular case, it was important that this have a medical and a -- an economic value proposition that made it accessible to all patients or as many as possible. And there's tens of millions of diabetes patients out there. Obviously, there's type 1s and insulin-dependent patients and there's type 2s trying not to be. And so the product has a much broader appeal across a much broader patient base. And in our case, we have a much lower cost and far greater automated manufacturing capability to not only allow that cost, but to allow for mass production. And that's the path we've taken. And we've gone at this from an access standpoint that's far more retail and direct-to-consumer-oriented. It's made a big difference. So I'd say, at this point, we're making healthy profits on this product. We have no intention of changing the value proposition at all. I mean, your question sort of suggests that we would raise price in order to be competitive. I'd say, you ought to be asking the other side what are they going to do…

Our next question comes from Bob Hopkins from Bank of America.

So 2 quick questions. First a product question and then an earnings growth question. On the product side, obviously, the context here is that Abbott is a company delivering absolutely top-of-class revenue growth. But the one thing in the quarter that I wanted to ask about was Neuromodulation. That was a little slower like the last quarter. I'm just curious, is your outlook for that business changed at all? Or this is just still temporary hiring issues? And when do you think you can return to more like double-digit growth in that division?

Okay. Thanks. I think it's more of the same from last quarter. And I do think this is temporary. I think it's going to take us couple of quarters to work through, let's call it, the commercial execution issue we have. And you don't fix that overnight, but we will fix it and fix it in the near term. And I do think that this is a business that should return to double-digit growth. So I can look at that as something that gets better for us. It was, obviously, very strong last year. It hit a stall point during this year. But I do think that upside is there. And it's strictly in our hands at this point. So yes, I'm pretty optimistic about it. Do you go to bed happy about it? No. Can you fix it? Yes, and we are.

Okay. Two other quick little things. What was the U.S. -- imminent U.S. product approval you guys were highlighting in your prepared remarks? And then I also wanted to just follow up really quickly on David's question on earnings growth. And I realized you start every year at 10%. The Street is modeling roughly 12% earnings growth for really the next couple of years. Given all the puts and takes, is that a reasonable place to start? Or could currency make that a little challenging?

Okay. First question is really easy. I was referencing HeartMate 3 and a new claim. Second question, good question. I know The Street is where it is. The Street, generally, in its consensus, hasn't tried to factor in or tried to model exchange. And we're all looking at the same exchange trends right now, even The Street. So I'd say, look, if I privately pull the 20 analysts or so that -- on the sell side that cover Abbott, or any company for that matter, you'd probably all say, "Well, this is my current estimate based on underlying growth, but I'm not sure how exchange is going to impact it." And secondly, I'm not sure how much everybody is going to try to absorb in their P&L and how much they're going to pass through in their estimates and so forth. I think we're all kind of in that boat together right now. Do I think that 10% to 12% range right now is reasonable? We start every year at double digits. And whatever -- I think, as I said earlier, the underlying growth of these businesses is there. There's puts and takes. There's ins and outs. There's not just product ins and outs. There's tax rate. Everybody that experience tax reforms is going to experience some adjustments in tax rates this year. There's puts and takes. We, obviously, made a change in some of our debt cost with euro debt. That's a positive for us. So there's a bunch of pluses and minuses we've got to sort out. The one that's hard to forecast in some way is exchange. And yet, we were on the dot to the penny or penny above or better every single quarter. So we tend to like a lot of precision on our forecasting.…

Our next question comes from Vijay Kumar from Evercore.

So Miles, maybe the first one on the sustainability question. If I'm looking at '19, you have MitraClip FMR indication, which is incremental. Libre continues its strength. You have HeartMate 3, which is incremental. Portico U.S. launch, which is incremental. A stable CRM outlook. Neuromod, your comps get easy. Alinity, it should be ramping in the U.S. It really feels like all the strength we've seen in '18, they should continue into '19. So maybe can you just talk about some drivers or how we should be thinking about the pluses and the minuses?

Well, Vijay, you forgot to mention Alere. You forgot to mention COAPT. You forgot to mention some improvements in EPD. It's interesting. I've never, in my career here, seen such breadth across the company in new products, new product launches, market conditions, et cetera. Even Nutrition, right now, is doing considerably better than it has the last couple of years. I wouldn't forecast better for Nutrition, but I like what it's doing right now. And EPD, it's in high growth or, at least, moderate to high growth markets with great tailwinds. It of course has a currency headwind, like everything else. But all of these things are performing really well. And even the ones that you can see and forecast and track pretty well, like Libre or Alinity, et cetera, they're actually accelerating. And that just gets better. So I think the sustainability of the growth and the diversity of it is a huge plus. It's not like we're reliant on a single product or a single country. We're not highly indexed in China. And we're not overdependent on a single product. There's just great diversity of growth opportunity across the board. And I think the -- I'm really proud of the company from a productivity and pipeline standpoint. That goes for St. Jude as well. As I've said a number of times, St. Jude, in the course of our acquisition negotiations with them continued to talk to us the veracity of their pipeline and how good it was. And to be honest, they were right, and that's proven. So I'm pretty bullish on just the diversity of opportunity here. And while we can try to point at 1 or 2 of them, I think Libre and Alinity stick out. But incremental matters. And incremental in any business here, whether it's HeartMate 3 or Neuro or even EPD or Alere or anything us, Portico, all of these things contribute to the growth of the company, and that's how we like it. We like every bit of this company performing well.

That's helpful. And maybe one for Brian. Brian, when you look at the guidance for Q4, any implication for '19? So gross margin is at 59.5%. That would imply an acceleration to Q4. Any particular reason why GM sequentially should step up? How much did FX cost you guys in the EPS? There was a lot of questions on why guidance was not raised for the year. And it looks like, at least, $0.05 cents hit in the back half here. And is that sort of a similar number we should be thinking about just given where FX is right when you think about for '19?

All right, Vijay. Let me start with the gross margin. Our underlying gross margin improvement has been strong. It's ticking up nearly about 0.5 point year-over-year, and that's largely the effect of our synergies that are going on, both with respect to Alere and its integration. And also contained synergies with St. Jude. And every year, we put an emphasis on improving our underlying gross margin of all of our businesses. So we had the healthy reinvestment back into the business. FX really not -- it mixes -- it moves around a little bit here and there. It changes every day, but it's not really having too much of an impact. So we're seeing close to 40 bps of gross margin improvement. That's all underlying for the year. Your observation on FX as far as earnings is pretty spot on. If you recall, we came out at the beginning of the year and we thought that FX would actually be a tailwind of about $0.05. It's probably now closer to that $0.03 to $0.04 down on a full year basis. So we're powering through that. We're powering through that with all the underlying performance that Miles has talked about with respect to all the businesses. So when you look under line, it's outstanding, very strong performance that carries momentum into 2019.

I would just add one comment that blame it on the CEO comment. I don't get overly worked up about raising in the fourth quarter. We've been ahead all year. We're performing strong. Like you, I'm looking at next year and the continuity and sustainability of it all. Whatever the fourth quarter is, it will be. And we're not going to miss -- that's incredibly unlikely. We are all observing that exchange is a bigger headwind. But when you get to giving guidance for the fourth quarter or raising, I think, generally, one is tweaking. And at this point in the year, I think tweaking for one quarter is kind of -- I'm looking at next year. And so I wouldn't read too much into that other than, look, the obvious. We all know exchanges is getting headier. And -- but beyond that, I think the story here is the underlying growth, and that is pretty strong and pretty sustainable. So don't read too much into it.

Our next question comes from Raj Denhoy from Jefferies.

Wonder if I could maybe ask about one of the areas in Medical Devices that continues to be sort of a little slower, and that's Vascular. So couple questions there. One, is there anything you can give us in terms of how the initial launch of the XIENCE Sierra stent is doing? And second to that, also the PHP, your percutaneous pump is still -- that trial is still halted. So any updates in terms of when that might get restarted?

Raj, this is Scott. Yes, I would just say with respect to the Vascular business, I think the big news item earlier this year was the U.S. approval of our XIENCE Sierra stent. That's off to a very good start. When you're going in to that, that physician feedback, I know it was very positive to our experience in Europe there. So we've added Sierra to a number of our contracts here in the U.S. We've actually recaptured several share points in the U.S. during the quarter. We also launched a product in Japan recently, and it's performing there very well. So the business had some momentum. But honestly, Sierra stent, it's is a very good product. There's a little bit of masking of that growth with respect to some of the noncommercial royalty revenue that we get, but that's noise. The commercial side of the business is really performing quite well with respect to that launch. With respect to PHP, that's a program we're still committed to very much so. We have not provided any updates on the time line of late. I would expect we will in the future at some point.

Okay. Fair. Maybe just -- for my second question just kind of a broader one on kind of the tone and outlook for the business broadly. Obviously, it depends a lot on the portfolio that various companies have. But is there anything you can offer in terms of how procedure volumes and pricing broadly are tracking in the industry right now?

Yes. No change, really. I mean, procedures and demand volume from that side of things are fairly constant to the way they've been running and trending for the last several quarters. Pricing in some of the segments, such as CRM and Vascular, is a modest headwind. But demand is strong, offsetting most of that. Those are really the only 2 areas of the Medical Device business where we think about price. The others are very healthy.

Our next question comes from Glenn Novarro from RBC Capital Markets.

Two quick questions. First, Miles, on Alere, you'll do $2 billion in revenue this year. I think that's hitting expectations. But Alere is going to be folded into organic growth in 2019. So can you help us think about Alere growth in 2019 and beyond? That's first question. And then quickly on Libre 2, can you give us an update on the U.S. approval timing?

Yes, let me do Alere first. So our first year -- you're spot on, on all your observations. Our first year was obviously stabilized, integrated, organized, put management in place, et cetera. All done, all done well and so on. And we benefited in this last year from -- and probably one of the stronger flu seasons in a long time, so the infectious diseases business in Alere, the infectious disease testing business did well in that context. Going forward, obviously, we now need to turn to driving growth. And I can't give you a forecast or prediction on that for '19 yet, or even '20 beyond that. But that's where the attention turns. I think we're mostly through all the disruption and/or transition synergies, et cetera, all that activity. In fact, I've got an update on that after this meeting later today. And at this point, our entire emphasis turns to what kind of sustainable growth rate we can now generate and trend out of that business. So I don't have a specific answer for you yet, Glenn. But I think that's one of our growth drivers of the future. And that's kind of next steps with it. And I'm sorry, what was the second half of your question?

Timing, Libre 2 in the U.S.

I might have to ask Scott for some help on that because I'm not sure we can give you timing on that.

Yes, that's right, Miles. We haven't provided timing yet on Libre 2 in the U.S. Obviously, we will bring an alarm version to the U.S. at some point in time. The current version is obviously doing quite well as well. So that's just another opportunity in the pipeline, but we have not provided specifics on time line yet.

I would tell you this. It should take a lot less time than it seems to. The U.S. lags Europe and the rest of the world on some of these approvals in a way that I find hard to explain, but it is what it is.

Our next question comes from Larry Biegelsen from Wells Fargo.

One on capital allocation, one on Nutrition. Miles, you've been paying down debt. You've been quiet on the M&A front in 2018. Do you expect that to change in 2019? And I just had one question on Nutrition.

Okay. Let me deal with that one first. Well, first of all, I think the organization has done a terrific job on cash generation and debt pay down. And I give Brian Yoor and the management team total credit for that because what we've done for cash management, debt management, debt pay down and stuff has been led by him and terrific job. And to be honest, when we took all the borrowing down in order to do the St. Jude and Alere acquisitions, our debt to EBITDA ratio was, gosh, I think, like, 4.3, something like that. And we made commitments to the rating agencies that we would get that down pretty fast. And we're down to, I think, 2. So we've obviously paid off a lot of debt very fast. And we're happy with the rate of that. And it gives us a lot of flexibility from a capital allocation or strategic flexibly standpoint. But will we continue to pay down debt? We will. But I think we also -- we have other capital needs, where, for example, we want to target our dividend in a certain range as a percent of our EPS. And we are completely able to do that and meet those targets and those goals for dividend payouts. Some of our capital attention has been paid to growth. And we are investing in Alinity, and we're investing in Libre. We're making a large investment in capacity expansion for Libre that, I think, you'll see drive even more growth out of Libre than you can see now and fulfill kind of the larger mass market ramp-up we see for that product. We're putting a fair bit of investment into the expansion of Alinity. So when we can invest our capital in growth not only near…

Very clear. And just last for me, Miles, on Nutrition. A year ago, that was the slowest growing business. That's clearly turned around. The international Pediatric Nutrition business is doing really well. Any color on what's going on in China? And lastly, on that, the Adult Nutrition business in the U.S. has been a little weak recently. Is that still private label competition? What's the outlook there?

Okay. Yes, I'll take the last first, Larry. This is Brian. With respect to the U.S., what you're seeing is the impact of a wind-down of a noncore product line for us. You'll see that here in Q3. Otherwise, the U.S. business will be growing. You'll see in Q4 as well. It's noncore to us and it's -- we've just decided to wind it down. That's the only thing going on in the U.S. With respect to China, the transition is going smoothly. The food safety law transition is going smoothly. I think behavior has been rational in the market. The market growth rates in China have been strong. And we're always fighting there to grow share. But our greater China business has done quite well this year. And we expect the markets there in China to remain strong and stable going forward on the pediatric side of the business.

Yes. I would only add that the whole Nutrition business, obviously, is doing a lot better this year than it did last year. Where it is right now, there's various countries or various segments of business where we want to do better. There's ups and downs. But overall, if you take it as a whole, a lot happier where it is today than where it was a year ago.

Our final question comes from Chris Pasquale from Guggenheim.

I wanted to follow up on the FX commentary and try to make sure we're all on the same page. As we think about next year, Brian, if rates were to stay where they are right now, what would the earnings impact from currency be in 2019?

It's going to be somewhere probably between 3% and 4% of our earnings. And we've seen that before. And as Miles said, we always work to mitigate as much of that as possible. And the great news is that we have a lot of underlying growth in the businesses and the sales growth that we're going to power through as much of that as possible.

And I would add to that, Chris. It always comes as a judgment trade-off. If you could predict currency for the whole year or beyond, that would be one thing, but we can't. And so we take a lot of different actions to mitigate the volatility of it or the impact of it. We've got a very sophisticated and, frankly, complex rolling hedging program on the currencies that we can hedge, so we take out a lot of the unpredictability with that. Obviously, over the long term, we're not currency traders and we're not trying to be, but we're trying to be able to make our earnings and our sales more predictable, more stable, more reliable in terms of what our investors want to see and, frankly, the impact on us, so we can plan and manage. That said, gosh, today's currency rates, if sustained, it'll be a heavy headwind. Do I think all of that somehow passes through to the investor? I do not. Do I think that the currency rates will be the same 3 months from now or the same 6 months from now? I do not. If you ask me, do I think they will be up or down? I have no idea. All I know is, as I told you earlier, we look at the right balance of what is right for us to try to mitigate or hedge or whatever we're going to do to perform to the investment identity that our investors expect of us and where are we in a prudent range of how we manage that balance and how we deal with exchange and so forth in the performance for our investors, and we always start with a double-digit target of growth. So a lot of moving parts, and we'll see. Right now, I think that's kind of the only elephant in the room for us. And everything else looks positive and strong and -- or is in our hands to manage. And the one that's not entirely in our hands to manage is what currency hands us. But then, we do have a lot of things to do to try to minimize its impact on the overall performance of the company for our investors.

And Brian, just to make sure that I'm hearing you correctly. You're saying about $0.10 headwind for next year, give or take.

It's a range. Exchange currency moves every day, if you look, 3% to 4%, about that.

Sure. Okay. And then Miles, just one last one on Alinity in the U.S. What's the latest on the timing there and when you think you'll have a broad enough menu in place to really make a big push domestically with that product?

Chris, this is Scott. I would just say, as you know, that the clinical chemistry and immunoassay instruments, the core business there, the instruments are approved. And we are building our test menu at a pretty ratable kind of rate quarter to quarter, so to speak, and making progress on that front. It will still take a few more quarters until we get what we consider a critical mass there. So you'll probably looking back half of 2019 on what we feel like we're really going to have the menu and the systems we need to go out and get business. Okay. Well, thank you, operator, and thank you for all of your questions. This now concludes Abbott's conference call. A webcast replay of this call will be available after 11 a.m. Central Time today on Abbott's Investor Relations website at abbottinvestor.com. Thank you for joining us today.

Ladies and gentlemen, thank you for participating in today's conference. This does conclude the program. You may all disconnect. Everyone, have a wonderful day.